Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: The next-PD study

Peritoneal Dialysis International

Volumn 34, Issue 7, 2014, Pages 766-774

  Nakayama, Masaaki ^a,b   Miyazaki, Masanobu ^c   Honda, Kazuho ^d   Kasai, Kenji ^e   Tomo, Tadashi ^f   Nakamoto, Hidetomo ^g   Kawanishi, Hideki ^h  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Miyazaki Clinic   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e Fuji City General Hospital   (Japan)

^f OITA UNIVERSITY   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

^h TSUCHIYA GENERAL HOSPITAL   (Japan)

Author keywords

Encapsulating peritoneal sclerosis; Neutral solution; Peritoneal dialysis

Indexed keywords

ICODEXTRIN; PERITONEAL DIALYSIS FLUID; PREDNISOLONE; BIOMATERIAL; DIALYSIS FLUID;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; COMORBIDITY; FEMALE; HEMODIALYSIS; HERNIA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SOCIAL ASPECT; ADVERSE EFFECTS; CLINICAL TRIAL; COMPARATIVE STUDY; EVALUATION STUDY; FOLLOW UP; JAPAN; KIDNEY FAILURE, CHRONIC; MORTALITY; PATHOPHYSIOLOGY; PROCEDURES; RENAL REPLACEMENT THERAPY; RETREATMENT; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGED; BIOCOMPATIBLE MATERIALS; DIALYSIS SOLUTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RETREATMENT; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84905012848     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2013.00074     Document Type: Article

References (39)

1. Nomoto Y, Kawaguchi Y, Kubo H, Hirano H, Sakai S, Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: A report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420-7.
2. Rigby RJ, Hawley CM. Sclerosing peritonitis: The experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
3. Lee HY, Kim BS, Choi HY, Park HC, Kang SW, Choi KH, etal. Sclerosing encapsulating peritonitis as a complication of long-term continuous ambulatory peritoneal dialysis in Korea. Nephrology 2003; 8(Suppl):S33-9.
4. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: A prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
5. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68:2381-8.
6. Brown MC, Simpson K, Kerssens JJ, Mactier RA; Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: A national cohort study. Clin J Am Soc Nephrol 2009; 4:1222-9.
7. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: Incidence, predictors, and outcomes. Kidney Int 2010; 77:904-12.
8. Gandhi VC, Humayun HM, Ing TS, Daugirdas JT, Jablokow VR, Iwatsuki S, etal. Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients. Arch Intern Med 1980; 140:1201-3.
9. Korte MR, Sampimon DE, Lingsma HF, Fieren MW, Looman CW, Zietse R, et al.; Dutch Multicenter EPS Study. Risk factors assodated with encapsulating peritoneal sclerosis in Dutch EPS study. Perit Dial Int 2011; 31:269-78.
10. Brown EA, Van Biesen W, Finkelstein FO, Hurst H, Johnson DW, Kawanishi H, et al.; ISPD Working Party. Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. Perit Dial Int 2009; 29:595-600.
11. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al.; Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
12. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51:182-6.
13. Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, et al., Peritoneal Biopsy Study Group of the Japanese Society for Peritoneal Dialysis. Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008; 3:720-8.
14. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant 1999; 14:1541-9.
15. Wieslander AP, Nordin MK, Kjellstrand PT, Boberg UC. Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 1991; 40:77-9.
16. Topley N, Coles GA, Williams JD. Biocompatibilitystudieson peritoneal cells. Perit Dial Int 1994; 14(Suppl 3):S21-8.
17. Wieslander AP. Cytotoxicity of peritoneal dialysis fluid-is it related to glucose breakdown products? Nephrol Dial Transplant 1996; 11:958-9.
18. Shostak A, Pivnik K, Gotloib L. Daily short exposure of cultured mesothelial cells to lactated, high-glucose, low-pH peritoneal dialysis fluid induces a low-profile regenerative steady state. Nephrol Dial Transplant 1996; 11:608-13.
19. Yang AH, Chen JY, Lin YP, Huang TP, Wu CW. Peritoneal dialysis solution induces apoptosis of mesothelial cells. Kidney Int 1997; 51:1280-8.
20. Nakayama M. The plasma leak-to-response hypothesis: A working hypothesis on the pathogenesis of encapsulating peritoneal sclerosis after long-term peritoneal dialysis treatment. Perit Dial Int 2005; 25(Suppl 4):S71-6.
21. Harel Z, Bargman J. Encapsulating peritoneal sclerosis. US Nephrology 2010; 5:71-5.
22. Holmes CJ, Shockley TR. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int 2000; 20(Suppl 2):S37-41.
23. Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 2000; 20(Suppl 5):S23-7.
24. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
25. Kawaguchi Y, Saito A, Kawanishi H, Nakayama M, Miyazaki M, Nakamoto H, et al. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: Diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int 2005; 25(Suppl 4):S83-95.
26. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2010, 2011 June (in Japanese).
27. Working Group Committee for Preparation of Guidelines for Peritoneal Dialysis, Japanese Society for Dialysis Therapy; Japanese Society for Dialysis Therapy. 2009 Japanese Society for Dialysis Therapy guidelines for peritoneal dialysis. TherApher Dial 2010; 14:489-504.
28. Kawanishi H, Nakayama M, Miyazaki M, Honda K, Tomo T, Kasai K, et al.; NEXT-PD Study Group. Prospective multi¬center observational study of encapsulating peritoneal sclerosis with neutral dialysis solution-the NEXT-PD study. Adv Perit Dial 2010; 26:71-4.
29. Fukui H, Hara S, Hashimoto Y, Horiuchi T, Ikezoe M, Itami N, et al.; PD + HD Combination Therapy Study Group. Review of combination of peritoneal dialysis and hemodialysis as a modality of treatment for end-stage renal disease. TherApher Dial 2004; 8:56-61.
30. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2011, 2012 June (in Japanese).
31. Ayuzawa N, Ishibashi Y, Takazawa Y, Kume H, Fujita T. Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: Recent clinicalpracticein Japan. Perit Dial Int 2012; 32:159-67.
32. Kawanishi K, Honda K, Tsukada M, Oda H, Nitta K. Neutral solution low in glucose degradation products is associated with less peritonealfibrosis and vascular sclerosisin patients receiving peritoneal dialysis. Perit Dial Int 2012 Nov 1 [Epub ahead of print].
33. Hamada C, Honda K, Kawanishi K, Nakamoto H, Ito Y, SakuradaT, eta/. Impact of neutral peritoneal dialysis fluid on morphological changes of peritoneum in peritoneal dialysis patients. Perit Dial Int 2012; 32(Suppl 3):S176.
34. Nakayama M, Itami Y, Kanazawa Y, Nakamoto H, Masakane I, Kawanishi H, et al. The report from the working committee of the preparation for revised JSDT PD guideline. Jpn Dial Soc 2011; 44:1199-204 (in Japanese).
35. Junor BJ, McMillan MA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial 1993; 9:187-9.
36. Mori Y, Matsuo S, Sutoh H, Toriyama T, Kawahara H, Hotta N. A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis 1997; 30:275-8.
37. Kuriyama S, Tomonari H. Corticosteroid therapy in encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2001; 16:1304-5.
38. Maruyama Y, Nakayama M. Encapsulating peritonealscle- rosis in Japan. Perit Dial Int 2008; 28(Suppl 3):S201-4.
39. Matsuo N, Yokoyama K, Maruyama Y, Ueda Y, Yoshida H, Tanno Y, et al. Clinical impact of a combined therapy of peritoneal dialysis and hemodialysis. Clin Nephrol 2010; 74:209-16.